Evelo biosciences, inc. (EVLO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Mar'17
Operating activities
Net loss

-23,041

-

-21,633

-20,941

-20,299

-

-15,857

-15,146

-10,500

-

Net Income (Loss) Attributable to Parent

-

-

-

-

-

-

-

-

-

-5,370

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

1,955

2,015

2,062

2,135

1,953

1,565

1,595

2,247

652

203

Depreciation expense

500

500

461

403

400

300

300

700

600

163

Change in fair value of warrant and debt derivative liability

-

-

-

-

-

0

0

285

121

90

Net (accretion of discount)/amortization of premium on marketable securities

0

0

3

46

115

0

0

0

0

-

Non-cash interest expense

50

-8

212

23

28

25

27

34

17

13

Non-cash lease expense

627

-

-

-

-

-

-

-

-

-

Gain on sale of fixed assets, net

3

-

-

-

0

-

-

-

-

-

Changes in assets and liabilities:
Prepaid expenses and other current assets

-298

-1,005

489

-77

221

-128

1,737

1,098

345

114

Accounts payable

565

-675

-1,234

1,227

97

-1,596

1,562

-143

-44

89

Accrued expenses and other current liabilities

146

787

987

1,735

185

-720

1,126

2,535

653

524

Operating lease liabilities

-624

-

-

-

-

-

-

-

-

-

Other liabilities

21

-

-

-

4

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

301

-228

545

45

Net cash used in operating activities

-19,515

-18,994

-19,637

-15,356

-17,993

-15,456

-12,660

-10,847

-8,316

-4,357

Investing activities
Proceeds from sales and maturities of investments

0

0

4,000

20,000

31,000

81,250

0

0

0

-

Purchases of property and equipment

435

463

1,089

604

876

1,235

1,564

1,663

1,000

151

Proceeds from sale of fixed assets

6

-

-

-

0

-

-

-

-

-

Net cash (used in)/provided by investing activities

-429

-463

2,913

19,396

30,124

28,581

-86,046

-1,663

-1,000

-151

Financing activities
Deferred issuance costs

-

-

-

-

-

-9,171

493

7,708

970

-

Net proceeds from the issuance of convertible preferred stock

-

-

-

-

-

0

0

-4

81,340

32,452

Proceeds from Issuance of Long-term Debt

-

-

-

-

-

0

0

0

4,975

-

Proceeds from the exercise of stock options

226

229

23

1

258

18

5

63

36

30

Net cash provided by financing activities

226

229

4,560

-55

258

18

-488

77,101

85,381

32,482

Net (decrease) increase in cash, cash equivalents and restricted cash

-19,718

-19,228

-12,164

3,985

12,389

13,143

-99,194

64,591

76,065

-

Net increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

27,974

Supplemental disclosure of cash flow information
Cash paid for interest

437

438

292

221

215

207

201

191

143

100

Noncash investing and financing activities
Property and equipment additions in accounts payable and accrued expenses

406

-44

79

39

172

172

-913

487

602

90

Issuance of warrants in connection with long-term debt facility

-

-

-

-

-

0

0

0

89

-

Accrued non-cash deferred offering costs

-

-

-

-

-

-

-

-

216

-

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

23